Welcome Guest to Happi

Subscribe Free: Magazine | eNewsletter

current issue October 2015
 •  MAC X Zac Posen for Spring 2016  •  L'Oréal USA Unveils Women in Science Honorees  •  Global Handwashing Day is Oct. 15  •  Oral Care Kit Recall  •  Algenist Rolls Out Lip Balm With SPF 15

Valeant To Buy Bausch & Lomb

Published May 27, 2013
Post a comment
Valeant Pharmaceuticals International will pay $8.7 billion to acquire Bausch & Lomb, the eye care company. Under the terms of the deal, Valeant will pay $4.5 billion to the investor group that owns Bausch & Lomb, led by private equity firm Warburg Pincus. It will also spend about $4.2 billion to repay Bausch & Lomb’s debt.


The agreement continues the flurry of deal-making in the health care industry, as companies seek to buy the growth they are hard-pressed to generate on their own. Announced merger volume in the sector this year is up 14% from the period a year earlier, even as takeovers have fallen 8%.

This acquisition follows Valeant's April purchase for Obagi skin care for $348 million.


blog comments powered by Disqus